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Supplementary Figure S1. Design and binding of mitoTALENs against two 
different pathogenic mtDNA mutations. A) mitoTALENs against the MERRF 
m.8344A>G mutation. B) mitoTALENs against the Leigh Syndrome m.13513G>A 
mutation. Version A of m.8344A>G mitoTALEN was found to be non-discriminat-
ing by SSA assays (supplementary figure S2). Base pair at position T0 is indicat-
ed in green and the mutated base pair in red (when they coincide, they are shown 
in red).
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Supplementary Figure S2. Single Strand Annealing assay of m.8344A>G-
TALENs. TALENs were expressed in yeast in a system whereas a Double Strand 
Break triggers a recombination event that can restore LacZ expression. The 
upper panel shows an example of the raw data with the m.8344A>G Version B, 
which displayed good specificity towards the mutant DNA sequence. The label 
indicates the position of the negative, intermediate and positive controls, as well 
as the triplicates of the test (#1-#3).
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Supplementary Figure S3. A small fraction of mitoTALEN monomer remains 
attached to the outside of the mitochondria. HEK293T cells were transfected 
with the plasmids coding for one of the m.8344A>G shortened mitoTALEN mono-
mers (version C monomer with 7.5 RVDs and the C8S9 mitochondrial targeting 
sequence). After 24 hours, mitochondria was isolated and treated with proteinase 
K as shown in the figure. Samples were analyzed by western blot with antibodies 
against FLAG. We also used an antibody against VDAC1, which is a mitochondri-
al protein known to be resistant to proteinase K. 
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Supplementary Figure S4. Sorting of cells transfected with mitoTALEN. 
Transmitochondrial osteosarcoma cybrids harboring the heteroplasmic levels of 
the m.8344A>G mutation were transfected with two plasmids expressing the two 
mitoTALEN monomers. Cells were sorted by the fluorescent markers eGFP and 
mCherry. Cells expressing both were termed “Yellow”. Cells expressing none 
were termed “Black”. 
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Supplementary Figure S5. Design and binding of short mitoTALENs against 
the m.8344A>G mtDNA mutation. The design and DNA binding domains are 
shown for the different combinations of sense and antisense monomers harboring 
the original (15.5 and 9.5) or reduced (10.5 and 7.5) RVDs. The combined short-
ened version was named “version C”. Base pair at position T0 is indicated in 
green and the mutated base pair in red.
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Supplementary Figure S6. Shortened mitoTALEN monomers are expressed 
and localized in mitochondria. (a) COS7 cells were transfected with the respec-
tive plasmids coding for the m.8344A>G shortened mitoTALEN monomers (ver-
sion C). After 48 hours, we immunostained the cells with antibodies against FLAG 
or HA. Cells were incubated with mitotracker before fixation. Western blots (b) 
showed the presence of specific proteins. Double bands may indicate incomplete 
removal of the MLS. 
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Production of cybrids with the ND5 m.13513G>A mutation. 
A skin biopsy was performed on a 5.8-year-old Caucasian girl with Leigh syndrome 
caused by the ND5 m.13513G>A mutation who is followed in the Mitochondrial-Genetics Clinic 
at The Children’s Hospital of Philadelphia, following informed consent per Children’s Hospital 
of Philadelphia Institutional Review Board (IRB) approved study #08-6177 (M.J.F., PI).  Her 
major clinical manifestations include Leigh syndrome involving progressive mid-brain and basal 
ganglia lesions with white matter signal abnormalities, severely disabling chorea and dystonia, 
truncal hypotonia and appendicular hypertonia, metabolic encephalopathy, primary lactic 
acidosis, global developmental delay with regression and complete loss of ability to stand 
unassisted, walk or speak, heat intolerance, intermittent ptosis with heat, progressive 
ophthalmoplegia and strabismus, bilateral optic atrophy, progressive fatigue, anxiety, swallowing 
dysfunction and failure to thrive requiring gastrostomy feeds, chronic constipation, wolff-
parkinson-white arrhythmia, renal tubular acidosis, and tracheostomy with intermittent ventilator 
support for respiratory failure and central sleep apnea.  Her fibroblast cell line was established in 
the Children’s Hospital of Philadelphia Clinical CytoGenomics Laboratory. Clinical diagnostic 
testing demonstrated variable heteroplasmy load in her different tissues and over time, including 
in blood (14% at 2.5 years, 46% at 4.9 years), urine (43% at 2.7 years), buccal (32% at 2.7 
years), and skin fibroblasts (67% at 5.8 years).   
Cybrid clones for the point-mutation m.13513G>A in ND5 were produced by fusing her 
dermal fibroblasts treated with 1 µg/ml actinomycin D (A-9415; Sigma-Aldrich) with 143B/206 
Rho Zero cells [24]. Individual colonies were manually picked and screened for heteroplasmy 
levels of the m.8344A>G and m.13513G>A mtDNA mutations respectively. The m.13513G>A 
point mutation has been reported and characterized in other patients [16, 17]. 
